Modular Engineered Treg News Today

Mar 17 2021 Read 132 Times Human antibodies developers IONTAS and FairJourney Biologics have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. Quell is harnessing the suppressive capacity of Tregs to develop engineered Treg cell therapies to address several conditions of immune dysfunction. Under the terms of the agreement, IONTAS / FJB will provide Quell with a diverse panel of novel target binders, ranging in affinitie...

IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement with Quell Therapeutics Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline March 9, 2021 CAMBRIDGE, UK, PORTO, PORTUGAL, and LONDON, UK — March 8, 2021 — IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB), leaders in the discovery and optimization of fully human antibodies, have announced that they have ent...

11 February 2021 · Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Synconas total commitment to Quell to £59.3 million · First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022   · Research programmes initiated in Type 1 Diabetes ("T1D") and Amyotrophic Lateral Sclerosis ("ALS") Syncona Ltd ("Syncona") announc...

Quell Therapeutics Expands Series A Financing to $84 Million Search jobs Quell Therapeutics Expands Series A Financing to $84 Million – Largest Series A in the Treg field –       London, UK – February 11 2021 – Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd (“Syncona”), who have committed an additional...